CVS Health Corporation CVS SPX

Q: What is the current share price of CVS Health Corporation (CVS)?

As of 2026-07-14 21:23 PDT, CVS Health Corporation (CVS) trades at $106.18 on NYSE. Its 52-week range is $57.30 to $106.18.

Q: What is the market capitalisation of CVS?

CVS Health Corporation (CVS) has a market capitalisation of $135.48B on NYSE.

Q: What is the P/E ratio of CVS?

CVS trades at a trailing price-to-earnings (P/E) ratio of 46.57. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.68.

Q: Does CVS pay a dividend?

CVS Health Corporation (CVS) currently offers a dividend yield of 2.61%.

Q: What is the return on equity (ROE) of CVS?

CVS has a return on equity (ROE) of 3.75%. Its return on capital employed (ROCE) is 2.83%.

Q: Is CVS a good stock to buy?

This page provides a data-driven analysis of CVS Health Corporation (CVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Healthcare Plans · United States

https://www.cvshealth.com

Company Profile ↓

$106.18

+71.01% 1Y

Mkt Cap$135.48B

P/E46.57

P/B1.68

Div. Yield2.61%

52W High$106.18

52W Low$57.30

Book Value$60.84

EPS (TTM)$2.28

Company Overview

CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

Why Investors Should Care

Dividend Income

Offers a dividend yield of 2.61%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $402.07B (+7.8% YoY); net profit $1.77B.
Trailing 12 Months Year-on-year growth — revenue +6.1%, earnings +63.1%.
5-Year Trend Long-term compounding — revenue CAGR 9.7%, profit CAGR -2.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	9.67%
1 Year:	6.10%

Compounded Profit Growth

5 Years:	-2.20%
1 Year:	63.10%

Stock Price Performance

1 Year:	+71.01%
6 Months:	+34.49%
3 Months:	+37.16%
1 Month:	+5.67%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 100% of range

$57.30 $106.18

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)65.87 · Neutral

Price Performance

1M+5.67%

3M+37.16%

6M+34.49%

1Y+71.01%

Valuation vs Sector

P/E of 46.57 is above the sector median of 25.41 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Attractive dividend yield of 2.61%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -2.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

46.57

Industry PE

25.41

Forward P/E

12.68

PEG Ratio

0.29

Book Value

$60.84

Price to Book

1.68

P/S

0.32

EV/EBITDA

12.77

Dividend Yield

2.61%

Growth (CAGR)

Revenue 5Y

9.67%

Profit 5Y

-2.20%

Revenue (YoY)

6.10%

Earnings (YoY)

63.10%

Profitability & Returns

ROCE

2.83%

ROE

3.75%

ROA

2.67%

Profit Margin

0.72%

Op Margin

4.12%

Gross Margin

13.39%

EPS (Latest Qtr)

$2.30

EPS (TTM)

$2.28

Balance Sheet & Liquidity

Debt/Equity

1.01

Quick Ratio

0.61

Current Ratio

0.87

Debt

$78.35B

Total Assets

$252.97B

Current Assets

$74.82B

Working Capital

$-11.59B

Ownership

Promoter Holding

0.06%

Chg in Prom Hold

-0.00%

FII / Inst Holding

90.28%

Chg in FII Hold

-0.06%

Financial Snapshot

Enterprise Value

$135.48B

Total Revenue (TTM)

$405.62B

EBITDA

$15.41B

Free Cash Flow

$5.20B

Operating Cash Flow

$10.33B

Shares Outstanding

1.28B

Gross Margin

13.39%

Payout Ratio

116.67%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CVS CVS Health Corporation SPX	106.18	46.57	$135.48B	2.61%	2.83%	3.75%	9.67%	-2.20%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	45.69B	46.71B	47.27B	-	61.40B	63.14B	64.55B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	6.63B	6.16B	6.40B	6.66B	7.30B	6.74B	7.01B	7.49B	7.61B	6.57B	6.93B	7.12B	7.90B	6.86B	7.20B	7.33B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	2.32B	2.13B	2.26B	2.33B	2.73B	2.19B	2.36B	2.82B	3.00B	1.80B	2.12B	2.50B	3.11B	2.00B	-1.37B	2.57B	824.00M	2.69B	3.33B	2.93B	3.04B	3.46B	4.68B	3.25B	3.58B	4.33B	3.06B	3.54B	4.67B	-3.92B	3.45B	3.23B	3.69B	2.27B	3.04B	832.00M	3.37B	2.38B	-3.21B	4.68B
Net Income	-	1.22B	1.27B	1.25B	1.50B	1.15B	924.00M	1.54B	1.71B	952.00M	1.10B	1.28B	3.29B	998.00M	-2.56B	1.39B	-419.00M	1.42B	1.94B	1.53B	1.75B	2.01B	2.98B	1.22B	2.22B	2.78B	1.60B	2.35B	3.03B	-3.41B	2.14B	1.90B	2.26B	1.11B	1.77B	87.00M	1.78B	1.02B	-3.98B	2.94B
Diluted EPS	1.14	1.07	1.12	1.11	1.34	1.04	0.86	1.43	1.59	0.92	1.07	1.26	3.22	0.98	-2.52	1.36	-0.37	1.09	1.49	1.17	1.33	1.53	2.26	0.93	1.68	2.10	1.20	1.77	2.29	-2.59	1.65	1.48	1.75	0.88	1.41	0.07	1.41	0.80	-3.13	2.30

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	76.33B	87.47B	98.22B	95.78B	107.08B	123.12B	126.76B	139.37B	153.29B	177.53B	184.76B	193.92B	256.78B	268.71B	292.11B	322.47B	357.78B	372.81B	402.07B
Gross Profit	16.11B	18.29B	20.36B	20.22B	20.56B	22.49B	23.78B	25.37B	26.53B	28.86B	28.55B	-	-	-	-	-	-	-	-
Operating Income	4.79B	6.05B	6.42B	6.14B	6.33B	7.21B	8.04B	8.80B	9.47B	10.39B	9.54B	4.02B	11.99B	13.91B	13.31B	7.95B	13.74B	8.52B	4.66B
Net Income	2.64B	3.20B	3.70B	3.43B	3.46B	3.86B	4.59B	4.64B	5.24B	5.32B	6.62B	-594.00M	6.63B	7.18B	8.00B	4.31B	8.34B	4.61B	1.77B
Diluted EPS	1.92	2.18	2.55	2.49	2.57	3.02	3.74	3.96	4.63	4.90	6.44	-0.57	5.08	5.46	6.02	3.26	6.47	3.66	1.39

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	60.96B	61.64B	62.17B	64.85B	66.22B	71.53B	74.19B	92.44B	94.46B	95.13B	196.46B	216.67B	222.45B	230.72B	233.00B	228.28B	249.73B	253.22B	253.54B
Total Equity	-	31.32B	34.57B	35.77B	37.70B	38.01B	37.65B	37.94B	37.96B	37.20B	36.83B	37.69B	58.23B	58.40B	63.86B	69.39B	75.08B	71.47B	76.46B	75.56B	75.21B
Cash & Equivalents	530.00M	1.06B	1.35B	1.09B	1.43B	1.41B	1.38B	4.09B	2.48B	2.46B	3.37B	1.70B	4.06B	-	5.68B	7.85B	9.41B	12.95B	8.20B	8.59B	8.45B
Long Term Debt	-	-	8.06B	8.76B	8.65B	9.21B	9.13B	12.84B	11.63B	26.27B	25.61B	22.18B	71.44B	71.35B	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	57.44B	137.91B	157.95B	158.28B	161.01B	157.62B	156.51B	173.09B	177.49B	178.16B
Current Liabilities	-	-	13.49B	12.30B	11.07B	11.96B	14.15B	15.43B	19.03B	23.17B	26.25B	30.65B	44.01B	45.76B	53.30B	62.02B	67.81B	69.42B	79.19B	84.61B	88.69B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	3.23B	3.95B	4.04B	4.78B	5.86B	6.67B	5.78B	8.14B	8.54B	10.14B	8.01B	8.87B	12.85B	15.87B	-	16.18B	13.43B	9.11B	10.64B
Investing Cash Flow	-3.08B	-4.58B	-1.07B	-1.64B	-2.41B	-1.85B	-1.83B	-4.04B	-13.42B	-2.47B	-2.88B	-43.28B	-3.34B	-5.53B	-	-5.05B	-20.89B	-7.61B	-5.87B
Financing Cash Flow	378.00M	929.00M	-3.23B	-2.80B	-3.46B	-4.86B	-1.24B	-5.69B	4.88B	-6.76B	-6.75B	36.82B	-7.65B	-7.70B	-	-10.52B	2.68B	-1.14B	-4.94B
Capital Expenditure	-1.80B	-2.18B	-2.55B	-2.00B	-1.87B	-2.03B	-1.98B	-2.14B	-2.37B	-2.22B	-1.92B	-2.04B	-2.46B	-2.44B	-	-2.73B	-3.03B	-2.78B	-2.83B
Free Cash Flow	1.43B	1.77B	1.49B	2.77B	3.98B	4.64B	3.80B	6.00B	6.17B	7.92B	6.09B	6.83B	10.39B	13.43B	-	13.45B	10.39B	6.33B	7.81B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	614.00M	-4.78B	359.00M	-172.00M
Share Buybacks	5.37B	23.00M	2.48B	1.50B	3.00B	4.33B	3.98B	4.00B	5.00B	4.46B	4.36B	0	0	0	0	3.50B	2.01B	3.02B	0
Dividends Paid	323.00M	383.00M	439.00M	479.00M	674.00M	829.00M	1.10B	1.29B	1.58B	1.84B	2.05B	2.04B	2.60B	2.62B	2.62B	2.91B	3.13B	3.37B	3.40B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	21.1%	20.9%	20.7%	21.1%	19.2%	18.3%	18.8%	18.2%	17.3%	16.3%	15.4%	-	-	-	-	-	-	-	-
Operating Margin %	6.3%	6.9%	6.5%	6.4%	5.9%	5.9%	6.3%	6.3%	6.2%	5.9%	5.2%	2.1%	4.7%	5.2%	4.6%	2.5%	3.8%	2.3%	1.2%
Net Margin %	3.5%	3.7%	3.8%	3.6%	3.2%	3.1%	3.6%	3.3%	3.4%	3.0%	3.6%	-0.3%	2.6%	2.7%	2.7%	1.3%	2.3%	1.2%	0.4%
ROE %	8.4%	9.2%	10.3%	9.1%	9.1%	10.3%	12.1%	12.2%	14.1%	14.4%	17.6%	-1.0%	10.4%	10.3%	10.7%	6.0%	10.9%	6.1%	2.4%
ROCE %	-	12.7%	13.0%	12.0%	12.0%	13.8%	14.3%	16.0%	13.7%	15.2%	14.8%	2.6%	7.1%	8.2%	8.1%	5.0%	8.1%	5.1%	2.8%

Shareholding Pattern

Insiders

0.06%

Institutions

90.28%

Public Float

90.33%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.87%	125.92M	$12.93B
2	Vanguard Capital Management LLC	6.48%	82.65M	$8.49B
3	Capital World Investors	6.05%	77.25M	$7.93B
4	State Street Corporation	4.65%	59.32M	$6.09B
5	Dodge & Cox Inc.	4.06%	51.78M	$5.32B
6	FMR, LLC	2.45%	31.20M	$3.20B
7	JPMORGAN CHASE & CO	2.31%	29.53M	$3.03B
8	Geode Capital Management, LLC	2.31%	29.46M	$3.02B
9	Vanguard Portfolio Management LLC	2.04%	26.00M	$2.67B
10	Invesco Ltd.	1.97%	25.14M	$2.58B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CVS

Google News ue, 14 Jul 2026

CVS Health (CVS) Expands GLP 1 Support, Does The Stock Look Fully Valued? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPOEFnQXdfdnBLZFhHYTFPWmZqVzM0OWlyRm1qMDg5M0FtcVlROW8xRGRLcjUtdl94blF0R1NWS1pRQm9SN0xoV1BNSk1ySTFxSjlfMHNQbGVsdkNfSkZCVlVvOUw0elJaMFlQM0xMOGR3d3ZyVE50NEszc2Y0VDl5N1dTQkJpYjhUdU1oMm…

Google News ue, 14 Jul 2026

FTC, CVS Health agree to settle PBM insulin suit - Modern Healthcare

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQajQxaG9rYXEyS3haR3EyY2FWS0hYNTNCQ3Btc2tPZWc2bzJrVTFVeWQxN1VzSWdQeXlUZFR3Ymw4MHNVV0RTeVdMNWRWcV9rYXJnOE1rRkRCeXYtZHdoWTRzYUg0MWR1LVR2aTdGclpfdW9tNHdicXB5Z2UyamRfU3hhTkJKQnhlYVQxU3…

Google News ue, 14 Jul 2026

FTC Reaches Settlement With CVS Health Over Insulin Prices - Barron's

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPR1hFNlIxeHJ3eHlyRmxtZktCbmpBQk1wZDg0MWJEc3Bxcm44TVNvOHgyeVpMSjVfUkk1bFlSOHI0SXM3a3VNUjZfak4zNzFIeWxhQXZlZWQ2UU1LZ3RIdjgzS2U3OHFEeTlIYm5aUDVCYjhJT0k5WlRmM1RCZGtsRFZvSzVFMjZ5Nmc?oc…

Google News ue, 14 Jul 2026

CVS Health (CVS) Following GLP 1 Expansion And Analyst Support Looks Near Fair Value - simplywall.st

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQQ1Vma3Y2azR2Mk9JMlVZWkhPOUtCWXhsWF9oQWlmZE5ackxGS1YxUDZxRjgyM3lCenFyX3RXVEc3Z3ByZFFxdWVHM3ZkNDJZNURiVEFhY3d2ZHZTbXN6Vi1SNHkybi12aGR6eHhtWFBfUDRKVU1hWU1SdTRzclhkNkpSUDEwTmV3MzJyMF…

Google News Mon, 13 Jul 2026

The Premium On CVS Stock Vs What Its Peers Deliver - Trefis

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOVUU4RW1wZkFqbkxkTjhuWU9IenZTXzNsQ3VrTElnRzA2TGtZWG1SU0Rmekx1cVRmMUw4QzU0NEg3ZnBpcEVaSktpZjU4RVJUS2xMNV9hbjVDN2V3UnhMc1JHTGRrRTljdGN6VWNvRU40TFBhSUJMMmkzcW5ONHRtVXRBb1M2UzFORW5XS0…

Google News ue, 14 Jul 2026

CVS Caremark Reaches FTC Settlement Over Drug Rebates and TrumpRx Deductible Credits - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPeW1nNHh0X3JJTHBmc1M5QXhKTHJ5ME5VSDZsT2hKVTZGUEJnNTR5RHc3eDFWRDRkZVZ5SEc2NDVGa0JIb0ZPSVN2Z09laUEyaEdEdjh4dmcxcFpQWkIzZ0ZYaV9HNDNVdTdLaG5odUh0ZFFEb0tGUkhmX0xyNG1xTzBLbV9TNlluNkt4U0…

CVS — Frequently Asked Questions

What is the current share price of CVS Health Corporation (CVS)?

As of 2026-07-14 21:23 PDT, CVS Health Corporation (CVS) trades at $106.18 on NYSE. Its 52-week range is $57.30 to $106.18.

What is the market capitalisation of CVS?

CVS Health Corporation (CVS) has a market capitalisation of $135.48B on NYSE.

What is the P/E ratio of CVS?

CVS trades at a trailing price-to-earnings (P/E) ratio of 46.57. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.68.

Does CVS pay a dividend?

CVS Health Corporation (CVS) currently offers a dividend yield of 2.61%.

What is the return on equity (ROE) of CVS?

CVS has a return on equity (ROE) of 3.75%. Its return on capital employed (ROCE) is 2.83%.

Is CVS a good stock to buy?

This page provides a data-driven analysis of CVS Health Corporation (CVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

CVS Health Corporation CVS SPX

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

CVS Health (CVS) Expands GLP 1 Support, Does The Stock Look Fully Valued? - Yahoo Finance

FTC, CVS Health agree to settle PBM insulin suit - Modern Healthcare

FTC Reaches Settlement With CVS Health Over Insulin Prices - Barron's

CVS Health (CVS) Following GLP 1 Expansion And Analyst Support Looks Near Fair Value - simplywall.st

The Premium On CVS Stock Vs What Its Peers Deliver - Trefis

CVS Caremark Reaches FTC Settlement Over Drug Rebates and TrumpRx Deductible Credits - Quiver Quantitative

CVS — Frequently Asked Questions

What is the current share price of CVS Health Corporation (CVS)?

What is the market capitalisation of CVS?

What is the P/E ratio of CVS?

Does CVS pay a dividend?

What is the return on equity (ROE) of CVS?

Is CVS a good stock to buy?

Explore More